1 / 4

Liver Cirrhosis Therapeutics

The Liver Cirrhosis Therapeutics Market is Forecast to Show Modest Growth Until 2017

rgunnam
Télécharger la présentation

Liver Cirrhosis Therapeutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Liver Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  2. The Liver Cirrhosis Therapeutics Market is Forecast to Show Modest Growth Until 2017 GlobalData estimated the global liver cirrhosis market to be valued at $1.56 billion in 2010. It is expected to grow to $2.03 billion with a Compound Annual Growth Rate (CAGR) of 3.8% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to increase in alcoholic liver disease, nonalcoholic steatohepatitis (NASH) and the large group of patients who were originally infected with hepatitis virus, who will be entering their third decade of chronic liver infection. Current Treatment Options are Moderately Successful in Meeting the Market Demand GlobalData analyzed that the available treatment options are moderately successful in meeting the market demand. Liver cirrhosis treatment is a supportive treatment and hence the drugs aim at treating the complications of the disease. Thus treatment of cirrhosis includes preventing further damage to the liver, treating the complications of cirrhosis and preventing liver cancer or detecting it early. There are drugs available for each of the complications and these off-label drugs have good safety and efficacy profiles. It is because of this that the unmet need is low even though there are no approved drugs for liver cirrhosis. However, there is still scope available for new entrants with new

  3. disease-modifying mechanisms of action, increased clinical performance and high safety profiles. There is scope for new entrants which will aim at reversal of the disease and increasing the survival rates because liver cirrhosis is a leading cause of morbidity and mortality worldwide. Emerging Therapies in Pipeline are Expected to Increase the Competition GlobalData analyzed that there are seven molecules in various stages of the pipeline. Lucassin, AST-120, HPN-100, and Copegus plus Pegasys are some of the late stage pipeline molecules. The market is dominated by off-label products and these molecules target the complications for which there are presently no approved therapies. These emerging therapies are likely to intensify the competition in the liver cirrhosis market as they have to compete with the generics. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Liver-Cirrhosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

  4. Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782

More Related